Search results
Showing 1751 to 1800 of 3008 results for all
NICE has developed a medtech innovation briefing (MIB) on 24/7 EEG SubQ for epilepsy .
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
the menopause is called anastrozole. However, this may not be suitable for all women; for example, women who have severe osteoporosis....
Evidence-based recommendations on balloon angioplasty with or without stenting for coarctation or recoarctation of the aorta in adults and children. This involves gently inflating a balloon in the narrow area of the aorta to widen it so blood can flow more easily.
View recommendations for HTG45Show all sections
Sections for HTG45
Axumin for functional imaging of prostate cancer recurrence (MIB172)
NICE has developed a medtech innovation briefing (MIB) on Axumin for functional imaging of prostate cancer recurrence .
NICE has developed a medtech innovation briefing (MIB) on Fungitell for antifungal treatment stratification .
NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .
Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)
Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.
Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments (TA1091)
Evidence-based recommendations on tarlatamab (IMDYLLTRA) for treating extensive-stage small-cell lung cancer after 2 or more treatments in adults.
Show all sections
Service user experience in adult mental health services (QS14)
This quality standard covers improving the experience of people using adult NHS mental health services. It describes high-quality care in priority areas for improvement.
View quality statements for QS14Show all sections
Sections for QS14
- Quality statements
- Quality statement 1: Empathy, dignity and respect
- Quality statement 2: Decision making
- Quality statement 3: Involvement to improve services
- Quality statement 4: Contacts for ongoing care
- Quality statement 5: Access to services
- Quality statement 6: Joint care planning
- Quality statement 7: Inpatient contact with staff
Find out how and where you can reuse NICE's content. Includes use of our content in the UK, use of our content internationally, use of our content for AI purposes, our content assurance process, and our information asset register.
stakeholder . Which topics are currently accepting stakeholder registrations? All topics in development can accept stakeholder...
Implantation of accommodating intraocular lenses for cataract (HTG134)
Evidence-based recommendations on implantation of accommodating intraocular lenses for cataract. This involves removing the clouded natural lens of the eye and replacing it with an accommodating lens to allow focusing on near and distant objects.
View recommendations for HTG134Show all sections
Sections for HTG134
Evidence-based recommendations on mini-incision surgery for total knee replacement. This involves using specially designed instruments to replace the knee using a smaller incision.
View recommendations for HTG220Show all sections
Sections for HTG220
stakeholder . Which topics are currently accepting stakeholder registrations? All topics in development can accept stakeholder...
Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry (MIB113)
NICE has developed a medtech innovation briefing (MIB) on the Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry .
Urethrotech UCD for difficult or failed catheterisation (MIB116)
NICE has developed a medtech innovation briefing (MIB) on the Urethrotech UCD for difficult or failed catheterisation .
SecurAcath for securing cerebrospinal fluid catheters (MIB107)
NICE has developed a medtech innovation briefing (MIB) on SecurAcath for securing cerebrospinal fluid catheters .
Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias (MIB276)
NICE has developed a medtech innovation briefing (MIB) on Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias .
Evidence-based recommendations on abemaciclib (Verzenios) with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence in adults.
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]
In development Reference number: GID-TA11454 Expected publication date: 23 July 2026
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]
In development Reference number: GID-TA11341 Expected publication date: 02 December 2026
This quality standard covers prevention of type 2 diabetes in adults (aged 18 and over) and care and treatment for adults with type 2 diabetes. It describes high-quality care in priority areas for improvement.
View quality statements for QS209Show all sections
Sections for QS209
- Quality statements
- Quality statement 1: Preventing type 2 diabetes
- Quality statement 2: Structured education programme
- Quality statement 3: Continuous glucose monitoring for adults on multiple daily insulin injections who cannot self-monitor using capillary blood glucose monitoring
- Quality statement 4: Continuous glucose monitoring for adults who use insulin and need help monitoring their blood glucose
- Quality statement 5: Treatment with an SGLT-2 inhibitor
- Quality statement 6: 9 key care processes
- Quality statement 7: Assessing the risk of diabetic foot problems on admission to hospital
Evidence-based recommendations on reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues. These procedures on high-risk tissues are intradural surgery on the brain (including the pituitary gland) and spinal cord, neuroendoscopy, and surgery on the retina or optic nerve.
Membership details, terms of reference and future meeting dates for our quality standards advisory committee.
Membership details, terms of reference and future meeting dates for our quality standards advisory committee.
Find out what guidance is being considered for development
Evidence-based recommendations on isatuximab (Sarclisa) plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable.
Show all sections
Evidence-based recommendations on garadacimab (Andembry) for preventing recurrent attacks of hereditary angioedema in people 12 years and over.
NICE has developed a medtech innovation briefing (MIB) on Colli-Pee for first void urine collection .
NICE has developed a medtech innovation briefing (MIB) on Thora 3Di for assessing asthma in children .
KODEX-EPD for cardiac imaging during ablation of arrhythmias (MIB260)
NICE has developed a medtech innovation briefing (MIB) on KODEX-EPD for cardiac imaging during ablation of arrhythmias .
NICE has developed a medtech innovation briefing (MIB) on OxyMask for delivering oxygen therapy .
Preventing suicide in community and custodial settings (NG105)
This guideline covers ways to reduce suicide and help people bereaved or affected by suicides. It aims to:
Evidence-based recommendations on laparoscopic partial nephrectomy. This involves making small ‘keyhole’ openings, either in the back or in the abdomen, to remove the section of kidney that contains the tumour.
View recommendations for HTG97Show all sections
Evidence-based recommendations on automated percutaneous mechanical lumbar discectomy. This involves using an automated device to cut and remove the part of the disc that’s pressing on the nerve.
View recommendations for HTG88Show all sections
Sections for HTG88
This quality standard covers the assessment and management of non-specific low back pain and sciatica in young people and adults aged 16 years and over. It describes high-quality care in priority areas for improvement.
View quality statements for QS155Show all sections
Sections for QS155
- Quality statements
- Quality statement 1: Risk stratification
- Quality statement 2: Referrals for imaging
- Quality statement 3: Self-management
- Quality statement 4: Gabapentinoids, antiepileptics, antidepressants and paracetamol for low back pain without sciatica
- Quality statement 5: Opioids for chronic low back pain without sciatica
- Quality statement 6: Spinal injections
- Update information
Percutaneous interlaminar endoscopic lumbar discectomy for sciatica (HTG411)
Evidence-based recommendations on percutaneous interlaminar endoscopic lumbar discectomy for sciatica in adults. This involves removing part of the damaged spinal disc to relieve the symptoms of sciatica.
View recommendations for HTG411Show all sections
Evidence-based recommendations on balloon cryoablation for Barrett's oesophagus. This involves freezing and destroying the abnormal cells using a balloon inflated with very cold gas.
We want you to be involved in our work - whether you’re commenting on our draft recommendations, taking part in guidance development or attending a committee meeting, your voice is important to us.
SepsiTest assay for rapidly identifying bloodstream bacteria and fungi (HTG400)
Evidence-based recommendations on the SepsiTest assay for rapidly identifying bloodstream bacteria and fungi.
Early value assessment (EVA) guidance on the Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies.
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning in people having external beam radiotherapy.
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) with bevacizumab (Avastin) for treating metastatic colorectal cancer after 2 systemic treatments in adults.
Evidence-based recommendations on dostarlimab (Jemperli) with platinum-containing chemotherapy for primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency in adults.
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)
Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.
Show all sections
Evidence-based recommendations on endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for gastro-oesophageal reflux. This involves inserting hydrogel implants into the wall of the oesophagus to narrow the entrance to the stomach and help prevent reflux.
View recommendations for HTG142Show all sections
Sections for HTG142
In development Reference number: GID-TA10868 Expected publication date: 15 July 2026
NICE has developed a Medtech Innovation Briefing (MIB) on the Space GlucoseControl system for managing blood-glucose in critically ill patients in intensive care